Evolocumab has been on the market since 2015 and was the subject of a very large CV outcome trial in adults (FOURIER; Sabatine MS, et al. N Engl J Med. 2017;doi: 10.1056/NEJMoa1615664.).

Evolocumab is one of three PCSK9 inhibitors being studied in large clinical trials. One out of three American adults is estimated to have high LDL cholesterol, according to the Centers for Disease ...

PARIS — In the first randomized trial designed to assess a PCSK9 inhibitor in patients with high-risk ACS, the addition of evolocumab to statin therapy was well tolerated and substantially ...

Alirocumab and evolocumab are fully humanized monoclonal antibodies that work by inactivating PCSK9, a protein responsible for LDL-receptor degradation. By blocking PCSK9, there is an increase in ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the ...

Evolocumab reduced by 15 percent the risk of the trial's primary endpoint--a composite of heart attack, stroke, hospitalization for worsening chest pain (angina), revascularization (such as ...

Evolocumab's efficacy was studied in four phase III double-blind, randomized, placebo or active control (ezetimibe) trials spanning 12 weeks. The trials involved more than 3,100 patients, and ...

Overall, 95.7% of patients in the evolocumab group and 37.6% in the placebo group reached an LDL-C target of less than 70 mg/dL at 8 weeks. An LDL-C of less than 55 mg/dL — a new target in the ...

66–75% reduction with evolocumab injections every 2 weeks or 63–75% on a 4-week schedule Patients achieved an LDL cholesterol level of <70mg/dL in 86–94% in the moderate-intensity statin ...

If evolocumab was discounted 29% to $10,311, the ICER is $165,689 per QALY gained, which is still above the threshold considered cost-effective. To achieve an ICER of $150,000, $100,000, and $50,000 ...

The researchers found that evolocumab significantly reduced ultracentrifugation LDL cholesterol by week 12 by 30.9% compared with placebo (P <0.001).

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the ...